SGLT2 inhibitors provide substantial therapeutic benefits in T2DM and cardiometabolic diseases and generally exhibit favorable pharmacokinetic properties with a low risk of clinically meaningful DDIs. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.